Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA(R) (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Supplemental New Drug Application -- submitted through FDA Real-Time Oncology Review program -- is based on positive Phase 3 data in patients aged 70 or younger
RARITAN, N.J., Nov. 8, 2019 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharma... Biopharmaceuticals, Oncology, FDA Janssen Pharmaceutical, Johnson & Johnson, IMBRUVICA, ibrutinib
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Marketing | New Drug Applications | Pharmaceuticals | Rituxan